Accelerating overseas expansion through meetings with 80 companies

Medical AI solution company AIDOT (CEO Jeong Jae-hoon) announced on the 25th that it participated in “MEDICA 2022” (hereafter MEDICA), held in Düsseldorf, Germany from November 14 to 17, where it showcased its distinctive medical AI technology and received a strong response.

MEDICA is one of the world’s top three medical device exhibitions. According to the article, the event drew about 5,000 companies from roughly 150 countries and approximately 150,000 attendees, and it also notes that the Cosmoprof exhibition venue drew 1,300 companies from 45 countries and around 40,000 attendees.

At the exhibition, AIDOT introduced its flagship cervical cancer screening system “Cerviray AI”, along with five AI solutions that are currently in preparation for commercialization or in development: △the alcoholic liver disease early diagnosis solution “BIO dot AI” △the carotid diagnostic system for stroke prevention “SONO dot AI” △the real-time gastrointestinal endoscopy screening system “GIGA dot AI.” AIDOT said it held meetings with more than 80 companies from around the world.

In particular, Cerviray drew extremely high interest from visitors: AIDOT said that all brochures prepared were exhausted before the booth closed, and sample purchases of the device were made on site.

A representative from AIDOT’s Global Sales & Marketing team said, “Among the AI-specialized companies participating in MEDICA, AIDOT was the only company that conducted an AI demonstration, and we were very pleased to be able to showcase our excellent technological capabilities. In the case of Cerviray, we concluded a contract with Vietnam’s Company L at this exhibition, and we also achieved results in securing potential customers for solutions beyond Cerviray,” adding, “Since we held meetings with many buyers, we will focus on overseas sales and marketing and do our utmost to generate tangible global revenue.”

About AIDOT

Since its founding in June 2014, AIDOT has been recognized for its technological capabilities, including being selected for KIC China and various government projects. It developed the AI-based cervical cancer interpretation system “Cerviray A.I.” and is expanding into global markets centered on Southeast Asia. It also co-developed an AI-based interpretation system combining carotid ultrasound and genomic information with the Department of Neurosurgery at Hallym University Chuncheon Sacred Heart Hospital, and it has completed development of an AI diagnostic system for gastroenterology integrating gastroscopy, capsule endoscopy, and colonoscopy.

Published: November 25, 2022 / Korea News Alliance